TESARO, Inc. (TSRO) Coverage Initiated at HC Wainwright
Investment analysts at HC Wainwright initiated coverage on shares of TESARO, Inc. (NASDAQ:TSRO) in a report issued on Thursday. The firm set a “buy” rating and a $158.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 28.46% from the stock’s previous close.
A number of other analysts also recently weighed in on the company. Credit Suisse Group set a $198.00 target price on TESARO and gave the company a “buy” rating in a research report on Wednesday, July 19th. Leerink Swann cut their target price on TESARO from $164.00 to $143.00 and set a “market perform” rating for the company in a research report on Tuesday, June 20th. ValuEngine downgraded TESARO from a “hold” rating to a “sell” rating in a research report on Monday, July 17th. Gabelli initiated coverage on TESARO in a research report on Friday, July 7th. They set a “buy” rating and a $175.00 target price for the company. Finally, Cann reiterated a “buy” rating and set a $199.00 target price on shares of TESARO in a research report on Friday, September 8th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $170.19.
Shares of TESARO (NASDAQ TSRO) traded up 1.46% on Thursday, reaching $123.00. The company had a trading volume of 774,323 shares. The company’s 50-day moving average price is $122.21 and its 200-day moving average price is $134.05. TESARO has a 52-week low of $106.64 and a 52-week high of $192.94. The firm’s market capitalization is $6.66 billion.
TESARO (NASDAQ:TSRO) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) EPS for the quarter, missing analysts’ consensus estimates of ($2.52) by ($0.30). TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The firm had revenue of $29.50 million during the quarter, compared to analyst estimates of $18.61 million. During the same period in the prior year, the company earned ($1.28) earnings per share. The business’s quarterly revenue was down 17.6% compared to the same quarter last year. On average, analysts predict that TESARO will post ($8.63) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This report was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.watchlistnews.com/tesaro-inc-tsro-coverage-initiated-at-hc-wainwright/1630405.html.
In other news, SVP Martin H. Jr. Huber sold 592 shares of the stock in a transaction dated Friday, September 22nd. The stock was sold at an average price of $118.60, for a total value of $70,211.20. Following the completion of the sale, the senior vice president now owns 6,943 shares of the company’s stock, valued at $823,439.80. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Edward C. English sold 10,862 shares of the stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $134.92, for a total value of $1,465,501.04. Following the completion of the sale, the vice president now directly owns 6,258 shares of the company’s stock, valued at approximately $844,329.36. The disclosure for this sale can be found here. In the last three months, insiders sold 35,692 shares of company stock valued at $4,628,976. Insiders own 40.50% of the company’s stock.
Hedge funds have recently modified their holdings of the company. Botty Investors LLC acquired a new stake in shares of TESARO in the second quarter valued at about $140,000. Nordea Investment Management AB acquired a new stake in shares of TESARO in the second quarter valued at about $167,000. Meeder Asset Management Inc. acquired a new stake in shares of TESARO in the first quarter valued at about $177,000. Oppenheimer Asset Management Inc. increased its stake in shares of TESARO by 3,042.6% in the second quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 1,430 shares during the period. Finally, BB&T Securities LLC acquired a new stake in shares of TESARO in the second quarter valued at about $222,000.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.